Find News

Filter articles

Applied Filters

Showing 61 to 70 of 225 results

WIPO and pharma industry join forces to promote patent access


The World Intellectual Property Organization (WIPO) has partnered with trade group the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to boost access to patent information.

Teva sells Paragard contraceptive for $1.1bn

Israel, US13-09-2017

Medical device firm Cooper Companies has agreed to acquire the global rights to Teva’s Paragard intrauterine device (IUD) for $1.1 billion.

AstraZeneca and Takeda enter agreement to develop Parkinson’s disease drug

Japan, UK29-08-2017

AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease.

Pfizer pneumonia patent approved in blow to MSF


The Indian Patent Office has approved pharmaceutical company Pfizer’s application to patent its Prevenar 13 (pneumococcal 7-valent conjugate) drug, despite claims by Médecins Sans Frontières that it is too obvious.

BIO 2017: The success story of OmniRat


The creator of OmniRat, the first human monoclonal antibody technology based on rats, outlined the success story of the project yesterday at the 2017 BIO International Convention.

Intellia Therapeutics granted China patent for CRISPR technology


Genome editing company Intellia Therapeutics has been granted a patent from China’s State Intellectual Property Office covering the CRISPR/Cas9 technology.

WIPO reveals new plan to fight tropical diseases


The World Intellectual Property Organization’s Re:Search has launched a new five-year guide to its activities in the fight against neglected tropical diseases, malaria and tuberculosis.

WHO to make biosimilars more available in poor countries


The World Health Organization will launch a pilot project for biosimilars to make costly cancer treatments more widely available in low and middle income countries.

Sawai acquires Upsher-Smith's generic business for $1.1bn

Japan, US21-04-2017

Japan-based Sawai Pharmaceutical has agreed to buy the generic drugs business of Upsher-Smith Laboratories for nearly $1.1 billion.

Takeda sheds off-patent drugs to focus on innovation


Takeda will sell a number of its off-patent drugs, used for treatment of diabetes, hypertension and peptic ulcers, to Teva Takeda Yakuhin for ¥28.5 billion.

Showing 61 to 70 of 225 results